BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 3,323,301 shares of common stock in Jade Biosciences Inc., representing 5.2% of the class, as of the event date of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 3,323,301 shares of Jade Biosciences Inc. common stock.
  • Percent of class: The reported position equals 5.2% of the outstanding common shares.
  • Sole voting power: BlackRock reported sole voting power over 3,231,840 shares.
  • Sole dispositive power: BlackRock reported sole dispositive power over 3,323,301 shares.
  • Shared voting and dispositive power: Both are reported as 0 shares.
  • Filer classification: BlackRock is identified as a parent holding company (type "HC"), organized in Delaware, with a principal address of 50 Hudson Yards, New York, NY 10001.
  • Triggering event date: The event requiring the filing occurred on September 30, 2026.

BlackRock's Schedule 13G Disclosure for Jade Biosciences Common Stock

According to the filing, BlackRock, Inc. submitted a Schedule 13G under the Securities Exchange Act of 1934 to report its beneficial ownership of common stock in Jade Biosciences Inc. (CUSIP 008064206), whose principal executive offices are located at 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, with the triggering ownership event dated September 30, 2026.

The filing states that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates," and that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units" in accordance with SEC Release No. 34-39538. The relevant subsidiaries that acquired the securities are identified in Exhibit 99 to the filing.

Regarding dividends and proceeds, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Jade Biosciences Inc.," and that no single person's interest exceeds five percent of the total outstanding common shares. BlackRock certified in the filing that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. disclosed in a Schedule 13G that it beneficially owns 3,323,301 shares, or 5.2%, of Jade Biosciences Inc. common stock, with sole voting power over 3,231,840 shares and sole dispositive power over the full 3,323,301 shares, as of September 30, 2026.